Related references
Note: Only part of the references are listed.Etanercept and infliximab induce the same serological autoimmune modifications in patients with rheumatoid arthritis
Marco Fusconi et al.
RHEUMATOLOGY INTERNATIONAL (2007)
Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity
Ehud Paz et al.
RHEUMATOLOGY INTERNATIONAL (2007)
Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease
George E. Reese et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
SB Hanauer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Impact of race and ethnicity on inflammatory bowel disease
D Basu et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease
CA Solem et al.
INFLAMMATORY BOWEL DISEASES (2005)
Laboratory testing in the rheumatic diseases: A practical review
CL Colglazier et al.
SOUTHERN MEDICAL JOURNAL (2005)
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
L De Rycke et al.
ARTHRITIS AND RHEUMATISM (2003)
Inflammatory bowel disease: new insights into pathogenesis and treatment
S Ardizzone et al.
JOURNAL OF INTERNAL MEDICINE (2002)
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
WA Faubion et al.
GASTROENTEROLOGY (2001)
Antineutrophil cytoplasmic antibodies in inflammatory bowel disease - Clinical role and review of the literature
G Lombardi et al.
DISEASES OF THE COLON & RECTUM (2000)
Share Paper
